Dr. Ailsa Snaith

Ailsa is a research scientist with a PhD from the University of Cambridge and previously worked as an academic clinician in Oxford having completed her medical training in Aberdeen. Ailsa has a deep commitment to improving patient outcomes and has been involved in numerous projects focused on the lived experiences of individuals affected by physical and mental health conditions. Her work includes contributions as a systematic reviewer to NICE Guidelines and Health Technology Assessments, highlighting her critical perspective on stakeholder involvement and evidence-based decision-making. She has also held postdoctoral and senior management positions at GlaxoSmithKline and Pfizer, respectively.

More recently, Ailsa has been involved in projects investigating the role of pathogens in chronic illness and neurodegeneration; she is particularly interested in tick-borne pathogens and the development of improved diagnostic and treatment pathways for affected individuals.

In addition to her research work, Ailsa is a trustee and board member of the Scottish Psychedelics Research Group, helping to raise awareness of emerging therapies in mental health. She is based in the Cairngorms National Park in Scotland.